UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 2030-15
Program Prior Authorization/Medical Necessity
Medication Xifaxan® (rifaximin)
P&T Approval Date 8/2014, 7/2015, 10/2015, 10/2016, 10/2017, 4/2018, 4/2019, 4/2020,
4/2021, 04/2022, 7/2022, 7/2023, 7/2024
Effective Date 10/1/2024
1. Background:
Xifaxan is an antibacterial agent indicated for the treatment of travelers’ diarrhea caused by
noninvasive strains of Escherichia coli in patients 12 years of age and older, for the risk
reduction of hepatic encephalopathy recurrence in adults and for the treatment of irritable
bowel syndrome with diarrhea (IBS-D). There is limited data to support the off label use of
Xifaxan for the treatment of inflammatory bowel disease.
This program requires a member to try a lower cost alternative before providing coverage for
Xifaxan. Members utilizing Xifaxan 200 mg for Travelers’ Diarrhea will automatically be
approved if prescribed for a one-time dose of 9 tablets.
2. Coverage Criteriaa:
A. Travelers’ Diarrhea
1. Authorization
a. Xifaxan will be approved based on both of the following criteria:
(1) Travelers’ diarrhea
-AND-
(2) History of failure, contraindication or intolerance to one of the following:
(a) Azithromycin (generic Zithromax)
(b) Ciprofloxacin (generic Cipro)
(c) Levofloxacin (generic Levaquin)
(d) Ofloxacin (generic Floxin)
Authorization will be issued for one month
B. Hepatic Encephalopathy
1. Initial Authorization
a. Xifaxan will be approved based on both of the following criteria:
(1) Hepatic Encephalopathy
© 2024 UnitedHealthcare Services Inc.
1
-AND-
(2) One of the following
(a) Both of the following:
i. Used as add-on therapy to lactulose
-AND-
ii Patient is unable to achieve an optimal clinical response with lactulose
monotherapy
-OR-
(b) History of contraindication or intolerance to lactulose
Authorization will be issued for 12 months
2. Reauthorization
a. Xifaxan will be approved based on the following criterion:
(1) Documentation of positive clinical response to Xifaxan therapy
Authorization will be issued for 12 months
C. Irritable Bowel Syndrome with diarrhea (IBS-D)
1. Initial Authorization
a. Xifaxan will be approved based on all of the following criteria:
(1) Diagnosis of IBS-D
-AND-
(2) History of failure, contraindication or intolerance to a tricyclic antidepressant
(e.g. amitriptyline)
-AND-
(3) One of the following:
a) History of failure, contraindication or intolerance to Viberzi
-OR-
b) History of or potential for a substance abuse disorder
© 2024 UnitedHealthcare Services Inc.
2
Authorization will be issued for 14 days
2. Reauthorization
a. Xifaxan will be approved based on all of the following criteria:
(1) Patient has experienced a recurrence of IBS-D after a prior 14 day course of
therapy with Xifaxan
(2) Patient has had a treatment-free period between courses of therapy
(3) Patient has not already received 3 treatment courses of Xifaxan for IBS-D in the
previous 6 months
Authorization will be issued for 14 days
D. Inflammatory Bowel Disease (e.g. Crohn’s Disease, Ulcerative Colitis, Diverticulitis)
(Off Label)
1. Initial Authorization
a. Xifaxan will be approved based on both of the following criteria:
(1) Diagnosis of Inflammatory Bowel Disease
-AND-
(2) History of failure, contraindication or intolerance to both of the following:
(a) Ciprofloxacin (generic Cipro)
(b) Metronidazole (generic Flagyl)
Authorization will be issued for 12 months
2. Reauthorization
a. Xifaxan will be approved based on the following criterion:
(1) Documentation of positive clinical response to Xifaxan therapy
Authorization will be issued for 12 months
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
© 2024 UnitedHealthcare Services Inc.
3
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limits may apply
4. References:
1. Xifaxan [package insert]. Bridgewater, NJ: Bausch Health US, LLC; October 2023.
2. Prantera C , Lochs H , Grimaldi M et al. Rifaximin-extended intestinal release induces
remission in patients with moderately active Crohn's disease . Gastroenterology 2012 ;
142 : 473 – 81 . e4
3. LaRocque, R. Travelers’s diarrhea: Treatment and prevention. In:UpToDate, Calderwood, SB
(Ed), UpToDate. Waltham, MA. (Accessed on May 2023).
4. Pimentel H, Lembo A, Chey W, et al: Rifaximin therapy for patients with Irritable Bowel
Syndrome without constipation. N Engl J Med 2011; 364(1):22-32
5. Lacey, BE, Pimentel, M, Brenner, DM, et. al. ACG Clinical Guideline: Management of Irritable
Bowel Syndrome. Am J Gastroenterol. 2021; 116 (1): 17-44.
6. AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel
Syndrome With Diarrhea. Gastroenterology. 2022.
7. Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014
Practice Guideline by the American Association for the Study of Liver Diseases and the European
Association for the Study of the Liver. Hepatology. 2014;60:715-735.
8. ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth. Am J Gastroenterol. 2020; 115:
165-78.
Program Prior Authorization/Medical Necessity – Xifaxin
Change Control
Date Change
8/2014 New program.
9/2014 Administrative change - Tried/Failed exemption for State of New Jersey
removed.
7/2015 Annual Review. Added irritable bowel syndrome with diarrhea (IBS-
D)
10/2015 Updated Step 1 agents for IBS-D. Updated references.
7/2016 Added Indiana and West Virginia coverage information.
10/2016 Updated Step 1 agents for IBS-D. Updated references.
11/2016 Added California coverage information.
10/2017 Annual review. Updated background and state mandate information.
References updated.
4/2018 Updated criteria for hepatic encephalopathy. Updated references.
8/2018 Administrative update due to correct typo.
4/2019 Annual review. Added statement regarding use of automated processes
and updated references.
4/2020 Annual review. Updated references.
4/2021 Annual review. Removed antispasmodic and antidiarrheal agent as a
step 1 option for IBS-D based on updated ACG guidelines. Added
reauthorization for hepatic encephalopathy. Updated references.
© 2024 UnitedHealthcare Services Inc.
4
4/2022 Annual review. No changes.
7/2022 Added step requirement of Viberzi for IBS-D.
7/2023 Annual review. Updated references.
7/2024 Annual review. Updated references.
© 2024 UnitedHealthcare Services Inc.
5